INVESTIGACION BIBLIOTECOLOGICA, ISSN 0187-358X, 2017, pp. 249 - 270
An informational metric study of San Luis Potosi state's institutional scientific productivity from 1920 to 2015 is presented. The informational metric...
Scientific productivity | LAWS | PUBLICATION | Bibliometrics | Scientific system | San Luis Potosi | INFORMATION SCIENCE & LIBRARY SCIENCE | PATTERNS | INFORMATION-RETRIEVAL | ELEMENTARY PARTICLE PHYSICS | COMMUNICATION
Scientific productivity | LAWS | PUBLICATION | Bibliometrics | Scientific system | San Luis Potosi | INFORMATION SCIENCE & LIBRARY SCIENCE | PATTERNS | INFORMATION-RETRIEVAL | ELEMENTARY PARTICLE PHYSICS | COMMUNICATION
Journal Article
2.
Full Text
Estudio bibliométrico del sistema de investigación local de San Luis Potosà (1920-2015)
Investigación Bibliotecológica: archivonomÃa, bibliotecologÃa e información, ISSN 0187-358X, 01/2018, Issue nesp1, p. 249
Se presenta un estudio métrico de 1920 a 2015 de producción cientÃfica de instituciones del estado de San Luis PotosÃ. Se construye un instrumento de medición...
Journal Article
3.
Full Text
Estudio bibliométrico del sistema de investigación local de San Luis Potosà (1920-2015)
Investigacion Bibliotecologica, ISSN 0187-358X, 2017, Volume 2017, pp. 249 - 270
Journal Article
Salud Pública de México, ISSN 0036-3634, 12/2014, Volume 56, Issue 6, pp. 573 - 574
Journal Article
Journal of Geography and Geology, ISSN 1916-9779, 09/2014, Volume 6, Issue 3, pp. 147 - 147
Land use changes are currently one of the indisputable factors in the alteration of processes and cycles of the aquifer system in the San Luis Potosi Valley....
Journal Article
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
MEDICINE, GENERAL & INTERNAL | BASE-LINE | EVENTS | EFFICACY | SAFETY | PEPTIDE-1 RECEPTOR AGONISTS | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Elderly
Journal Article
Salud Publica de Mexico, ISSN 0036-3634, 2014, Volume 56, Issue 6, pp. 573 - 574
Journal Article
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 131 - 138
Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for cardiovascular disease. We assessed the...
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
MEDICINE, GENERAL & INTERNAL | BASE-LINE | LIRAGLUTIDE | INCRETIN | CARDIOVASCULAR OUTCOMES | DISEASE | Myocardial infarction | Therapy | Peptides | Glucagon | Cardiovascular disease | Risk factors | Incidence | Randomization | Motivation | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Health risks | Risk analysis | Disease control | Agonists | Microvasculature | Diabetes | Kidney diseases | Renal replacement therapy | Gastrointestinal surgery | Cardiovascular diseases | Health risk assessment
Journal Article